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Background: Funders of medical research the world over are increasingly seeking, in research assessment, to
complement traditional output measures of scientific publications with more outcome-based indicators of societal
and economic impact. In the United Kingdom, the Higher Education Funding Council for England (HEFCE)
developed proposals for the Research Excellence Framework (REF) to allocate public research funding to higher
education institutions, inter alia, on the basis of the social and economic impact of their research. In 2010, it
conducted a pilot exercise to test these proposals and refine impact indicators and criteria.
Methods: The impact indicators proposed in the 2010 REF impact pilot exercise are critically reviewed and
appraised using insights from the relevant literature and empirical data collected for the University of Oxford’s REF
pilot submission in clinical medicine. The empirical data were gathered from existing administrative sources and an
online administrative survey carried out by the university’s Medical Sciences Division among 289 clinical medicine
faculty members (48.1% response rate).
Results: The feasibility and scope of measuring research impact in clinical medicine in a given university are
assessed. Twenty impact indicators from seven categories proposed by HEFCE are presented; their strengths and
limitations are discussed using insights from the relevant biomedical and research policy literature.
Conclusions: While the 2010 pilot exercise has confirmed that the majority of the proposed indicators have some
validity, there are significant challenges in operationalising and measuring these indicators reliably, as well as in
comparing evidence of research impact across different cases in a standardised manner. It is suggested that the
public funding agencies, medical research charities, universities, and the wider medical research community work
together to develop more robust methodologies for capturing and describing impact, including more valid and
reliable impact indicators.Background
In the United Kingdom, universities and other higher
education institutions (HEIs) conduct more than £1.3
billion worth of research in clinical medicine annually,
most of which is funded by United Kingdom (UK) and
European Union (EU) government agencies as well as
medical research charities. Owing to the support of the
public and taxpayers, the UK has developed some of the
strongest and most productive clinical medicine research* Correspondence: head@medsci.ox.ac.uk
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reproduction in any medium, provided the orbases in the world. According to Thompson Reuters
(ISI) bibliometric indicators, the UK’s clinical sciences
research is second only to the USA. With just 0.9% of
the world’s population, the UK produces 8.7% of world
publications in clinical sciences and generates 12.7% of
world citations [1].
Increasingly, however, funders of medical research
the world over are seeking, in research assessment, to
complement traditional output measures of scientific
publications – such as number of publications, num-
ber of citations, impact factor, research funding, de-
gree of co-authorship, and h-index [2,3] – with more
outcome-based indicators of societal and economic impact
[4-15]. The medical research and academic community isl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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health research [16,17], how to “best report to taxpayers
and philanthropists on the societal value produced by
the monies entrusted to [it]” [18], and how key indica-
tors in academic medicine “may promote effective
growth and development in a dynamic clinical, training,
and research environment” [19]. Medical schools around
the world are striving to achieve and demonstrate a
greater impact on the health needs of the populations
and societies they serve as part of their social account-
ability strategies [20-23].
For medical research charities, an important rationale
for more outcome-based evaluation of the research they
fund is to fulfil more effectively the wishes of their bene-
factors, e.g. “the improvement of the physical conditions
of mankind” in the case of the Sir Henry Wellcome
Trust [24]. For some collection-based charities, such as
the UK’s Arthritis Research Campaign, the virtue of
demonstrating the outcomes of research they fund lies
in that demonstrable outcomes help them compete for
contributions [25]. Overall, medical research charities
hope that improved understanding of how research
funding impacts on health outcomes will enable them
to [26]:
 “show accountability and good research governance
to their stakeholders;
 enhance public perception and understanding of
biomedical science and the scientific process;
 and allow the development of more effective
strategies in research and development to increase
the likelihood of ‘successful’ research outcomes.”
For EU and UK government agencies, the agenda be-
hind outcome measures transcends health to encompass
innovation, economic growth, and social progress. The
Lisbon European Council (2000) set out a strategy for
making Europe “the most competitive and dynamic
knowledge-based economy in the world, capable of sus-
tainable economic growth with more and better jobs and
greater social cohesion” [27]. In conjunction with this
strategy, the European Commission has argued for
“increased and more effective public expenditure [on R&D
and innovation]” [28], and for “the development and pilot-
ing of indicators designed to measure the social and eco-
nomic impact of research in general, and of European/
international collaborative research in particular” [29]. In
the UK, the research strategy for the National Health Ser-
vice (NHS) “Best Research for Best Health” aims both “to
improve the nation’s health and increase the nation’s
wealth” [30], while the performance monitoring frame-
work developed by the UK’s National Institute for Health
Research (NIHR) links early performance indicators with
longer-term research impacts [31].In 1989, the UK was the first country in the world to im-
plement a performance-based research funding system,
the Research Assessment Exercise (RAE), and since then
at least thirteen more countries, including Australia, New
Zealand, Hong Kong (China), and several EU countries,
have introduced such systems [32]. The RAE was con-
ducted approximately every five years to assess higher
education-based research activity for the purpose of allo-
cating core public research funds to universities and other
HEIs. Those who performed well had their public research
funding increased, while those who underperformed had
it decreased. Traditionally, the focus of the RAE has been
on “quality”, seen as academic or scholarly excellence and
assessed through the criteria of rigour, originality and sig-
nificance, coupled with other indicators, such as academic
esteem, viability of research environments, and research
capacity [33]. These criteria have been interpreted in each
subject-group (known as “unit of assessment”) by dedicated
sub-panels of assessors, who peer-reviewed the different
parts of institutional submissions and used a common
grading scale to arrive at quantified quality profiles.
In 2014, the RAE will be replaced by a new performance-
based research funding system – the Research Excellence
Framework (REF). The aims of the REF are similar to the
RAE, i.e. primarily to provide a basis for resource alloca-
tion, accountability for public investment in research, and
benchmarking information and reputational yardsticks for
the higher education sector [34]. A major new development
in the REF was the decision to base the future allocation of
public research funding to universities and other HEIs on,
inter alia, the social and economic impact of research [35].
The introduction of impact assessment was wrought with
controversy as it was perceived by many, especially in social
sciences and humanities, as “a threat to researchers’ auton-
omy and to fundamental academic freedoms” [36]. Given
that universities in the UK are independent from the gov-
ernment and that academic professions are self-regulated,
elected politicians in the government cannot hold univer-
sities directly accountable for the type of research they
choose to conduct. Therefore, in order to achieve its goal
of increasing the economic and social impact of publicly-
funded research within specified time horizons, the govern-
ment introduced funding incentives for universities to en-
gage in high-impact research. This decision was viewed by
many as the government’s attempt to limit universities’
freedom to pursue all forms of research, including research
that may not necessarily lead to high impact, and to hold
independent academic professions accountable for some-
thing that they had not chosen themselves [36].
In academic clinical medicine, the introduction of im-
pact assessment was perceived as less controversial. Due
to their focus on translational research and health out-
comes, academic physicians and scientists were used to
outcome-based indicators, and there had been growing
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to strengthen their social accountability [22]. The latter is
defined by the World Health Organization as "the obliga-
tion to direct their [medical schools’] education, research
and service activities towards addressing the priority
health concerns of the community, region, and/or nation
they have the mandate to serve. The priority health con-
cerns are to be identified jointly by governments, health
care organisations, health professionals and the public”
[20]. Importantly, the notion of social accountability im-
plies that it is measured and reported back to society [23].
The proposals to include indicators of social and eco-
nomic impact in the UK’s performance-based research
funding system were first tested in a pilot exercise run
by the Higher Education Funding Council for England
(HEFCE) on behalf of four UK higher education funding
bodies in 2010. The impact pilot exercise aimed to de-
velop a coherent approach to assessing impact in the
REF. It invited participating institutions to submit details
of economic and societal impacts in several disciplines
(including clinical medicine), in the form of a) an impact
statement, and b) case studies of specific impacts, pro-
duced using a generic impact template. The impact
statement was designed to provide “evidence of the
breadth of the unit’s contributions to society or the
economy” [37]. It had to include any appropriate indica-
tors of impact, collaboration, and other interactions with
research users (such as the NHS, UK and EU govern-
ment, home and overseas industry, charities, and re-
gional development agencies), which were deemed
applicable to the whole subject-group (“unit of assess-
ment”). HEFCE intended to use this information to-
gether with research income from key research users to
explore the feasibility of developing standardised impact
indicators. The case studies were designed to illustrate
the unit’s contributions in more detail. Although partici-
pating institutions could choose which impacts to in-
clude, they were encouraged to submit case studies
illustrating a wide range of impacts. For every ten faculty
members, participating institutions were asked to submit
one case study. The generic impact template for each
case study included information on 1) the nature and ex-
tent of a specific impact, including appropriate indica-
tors; 2) how the unit’s research activity contributed to
this impact; and 3) references to external sources that
could corroborate the information about the impact and
its underpinning research [37].
For the purpose of the 2010 pilot exercise, HEFCE
defined research impact as “any identifiable benefit
to, or positive influence on, the economy, society,
public policy or services, culture, the environment or
quality of life,” and provided HEIs with a “common
menu” of impact indicators in the following broad
categories [37]: Delivering highly skilled people;
 Creating new businesses, improving the
performance of existing businesses, or
commercialising new products or processes;
 Attracting R&D investment from global business;
 Better informed public policy-making or improved
public services;
 Improved patient care or health outcomes;
 Progress towards sustainable development, including
environmental sustainability;
 Cultural enrichment, including improved public
engagement with science and research;
 Improved social welfare, social cohesion or national
security;
 Other quality of life benefits.
On the basis of the evidence gathered through the
2010 pilot exercise [38] and a public consultation [39],
the funding bodies decided to invite HEIs to submit, in
the next round of research assessment under the REF in
2014, a statement about their approach to, and strategy
for, enabling research impact, together with a set of im-
pact case studies containing “a narrative that includes
indicators and evidence as appropriate to the case being
made” [35]. The definition of impact was more clearly
focused on non-academic effects, changes or benefits
[34]. It was also decided that the assessment of impact
will account for 20% of the overall assessment outcomes,
alongside the quality of research outputs (65%) and the
vitality of the research environment (15%) [35]. The
funding bodies set out the generic assessment criteria of
“reach” (or breadth) and “significance” (or intensity) of
impact, while the discipline-specific interpretations of
these criteria were left to the panels and sub-panels re-
sponsible for the actual assessment [40]. The “common
menu” of indicators was dropped from the generic guid-
ance, but re-worked forms of it were maintained in the
statements of criteria and working methods of the four
main panels of assessors, including Panel A, of which
clinical medicine is a part [40].
As indicated by the rich body of research on the influ-
ence on HEIs of the previous rounds of the RAE, the
newly-introduced impact assessment for resource alloca-
tion purposes via the REF is likely to affect strategic
decisions in HEIs at institutional and departmental level,
as well as the individual behaviour of researchers and re-
search teams [41-45]. Given the aims of the REF and the
weighting of 20% given to impact in the overall outcome,
HEIs in the UK are already keenly aware of the higher
stakes involved. Particularly challenging is the fact that
the development of impact assessment methodologies
has still to address major difficulties, such as that of
causality, of operationalisation, of attribution, of track-
ing long-term impacts, of combining quantitative and
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sensitivity to field and context specificities with that for
comparability across cases [12,36,46-51]. In addition,
prior to the REF, institutions and individual researchers
had not been expected to closely monitor and account
for impact-related activities; thus, at the start of the
current REF assessment period, impact records, if any,
were at best patchy, and fit-for-purpose information and
management systems were not available. Some competi-
tively allocated project funding streams (such as those by
the Research Councils UK, including the Medical Re-
search Council) introduced explicit requirements to
report on engagement, dissemination or knowledge ex-
change activities. However, as the overlap between these
activities and the REF definition of impact was only
partial, the systems that had been put in place for this
purpose sometimes added to the confusion, rather than
making it easier, about reporting on impact for REF
purposes. As such, the forthcoming REF is facing ser-
ious difficulties in simultaneously attempting to concep-
tualise, operationalise, and assess impact.
In this article, we critically review and appraise the im-
pact indicators used by HEFCE to inform the 2010 im-
pact pilot exercise, using insights from the relevant
literature and empirical data gathered for the University
of Oxford’s submission to the pilot exercise in clinical
medicine. We show that, while the majority of the pro-
posed indicators have some validity, there are significant
challenges in operationalising and measuring these indi-
cators reliably, as well as in comparing evidence of re-
search impact across different cases in a standardised
and consistent manner. We argue that this unevenness
needs to be addressed early on in the design of method-
ologies aimed at capturing and assessing impact, and
that more work, involving collaboration among research,
beneficiary, and funding partners, is required to ensure a
research-informed approach to impact assessment in the
UK REF and beyond.
In what follows, we begin with a methods section
explaining why clinical medicine at the University of
Oxford provides a critical opportunity to study impact
assessment, and describing the design of the 2010 im-
pact pilot exercise. We then present the empirical data
and discuss the strengths and limitations of the pro-
posed impact indicators using insights from the relevant
biomedical and research policy literature. Finally, we draw
conclusions and make recommendations for the develop-
ment and validation of impact indicators.
Methods
A total of 29 HEIs, including the University of Oxford,
participated in the 2010 impact pilot exercise in one or
more subject-groups (“units of assessment”): clinical
medicine, physics, earth systems and environmentalsciences, social work and social policy & administration,
and English language & literature [37]. Clinical medicine
is the largest subject-group, by research income, in the
UK, and as such it provides a critical opportunity for the
development and validation of impact indicators. Out of
£4,145 million worth of research grants and contracts
awarded to UK HEIs in 2008/09 (i.e. at the end of the
census period for the pilot exercise), clinical medicine
awards accounted for £1,347 million across all HEIs,
including £174 million awarded to the University of
Oxford alone (Figure 1) [52].
This article uses administrative data from the University
of Oxford to operationalise the “common menu” of impact
indicators proposed by HEFCE and to test their relevance
to research practice in clinical medicine. In 2010, in prep-
aration for the pilot exercise, the university’s Medical
Sciences Division collected a first round of relevant ad-
ministrative data from university sources. In addition, the
Division developed an online administrative survey, based
on the HEFCE “common menu” of impact indicators; the
survey was conducted among the faculty members form-
ing the university’s clinical medicine “unit of assessment”.
In 2011, a second round of data was gathered by the
authors from the relevant administrative units of the uni-
versity and publicly available sources specifically for the
purpose of the current study including updated data on
commercialisation activities, clinical trials, and financial
indicators. The university’s Clinical Trials and Research
Governance Team reviewed the study and deemed neces-
sary no further ethics committee clearance. Institutional
approval for the use of the administrative data used in the
paper was secured from the Medical Sciences Division.
In March 2010, instructions and an electronic link to
the impact assessment survey were e-mailed to the 289
faculty members who were most likely to participate in
the 2014 REF, i.e. those who participated in the 2008 RAE
in the “units of assessment” relevant to clinical medicine
and who at the moment of the survey had active university
e-mail accounts. The survey included 15 open-ended
questions structured around the proposed impact indica-
tors, e.g. “If in the period between January 2005 and
December 2009, you participated on public policy/advis-
ory committees, please indicate how many times and spe-
cify their topics and your capacity”. The survey also
included a personal details section and three questions
prompting respondents to provide open-ended comments
or thoughts on the impact indicators, on the impact pilot
exercise, and on how the Medical Sciences Division should
organise the collection of impact data on a regular basis in
the least burdensome way for faculty.
The survey received a total of 139 responses, including
four responses after the closing date, which all were
accepted for analysis here (48.1% response rate). The





















Figure 1 Top 10 UK HEIs by income from research grants and contracts in clinical medicine, 2004/05-2008/09. Source: Higher Education
Information Database for Institutions (heidi), 2010.
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search setting [53] and elsewhere [54]. Sample proportions
by gender, career stage, and staff category were similar to
the population surveyed; however, women, early-career
researchers, and mid-career researchers were slightly over-
represented, whilst senior researchers were slightly under-
represented; there were also slight discrepancies within
staff categories (Table 1). Staff grades from the university’s
payroll were used to determine career stage and staff cat-
egory, and these were unknown for 5 researchers (1.7%),
who were no longer on the payroll. Overall, the survey
provided a unique and adequate insight into individual
and aggregated evidence of impacts and into clinical medi-
cine faculty members’ views on the nature and appropri-
ateness of the impact indicators proposed by HEFCE.Table 1 Demographic and professional characteristics of














Category A, university scientists 71.3% 75.5%
Category A, university clinical academics 18.7% 18.0%
Category C, MRC scientists and NHS clinicians 8.3% 6.5%
Unknown 1.7% 0.0%Results and discussion
In the main part of this paper, we assess the scope and
relevance to clinical medicine research of a range of mea-
sures that operationalise the impact indicators proposed.
We unpack each of the potential indicators listed above,
track its rise as an aspect of research deemed important
by a range of interested parties, discuss some of the mea-
sures most commonly used to assess it, and illustrate the
strengths and limitations of these measures using data
from clinical medicine in Oxford. Data are presented in
anonymised and aggregated format and relate to the five-
year census period January 2005 – December 2009, unless
otherwise stated.
Delivering highly skilled people
Staff movement between academia and industry
Increasing human mobility between academia and in-
dustry is a desired goal not only in the UK, but also in
EU and OECD countries – it is perceived to enhance
knowledge transfer in both directions and to offer better
employability and career prospects for researchers [55-
57]. The Lambert Review of business-university collab-
oration in the UK concluded that “the best forms of
knowledge transfer involve human interaction” [58].
Moreover, research evidence from the US suggests that
inter-sectoral collaborations and staff movements from
academic to industrial jobs and vice versa are positively
associated with researchers’ productivity, most likely, be-
cause of the accumulation of scientific and technical
human capital in multiple settings [59,60]. There is also
some normative guidance on the desirable rate of staff
movement. Following the 2005 summit of EU leaders in
Hampton Court, the Aho Report on creating an innova-
tive Europe suggested that “[t]en per cent of the work-
force in each year should be moving” [61].
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Oxford showed minimal full-time movement of tenured
researchers between the sectors, a significant number of
university researchers worked in industry part-time, on
temporary assignments, or in their own time; conversely,
many industry researchers held visiting positions in the
university. More than one-third of respondents to the
impact assessment survey (37%) reported spending time
working in, or providing advice and consultancy to, in-
dustry, through ad hoc research projects and collabora-
tions, long-term industrial-academic partnerships, or
permanent appointments in companies’ scientific and ad-
visory committees and non-executive boards. The range
of companies included global biotechnology and pharma-
ceutical companies, small and medium enterprises, and
university spin-outs. The amount of time spent in industry
by each respondent ranged from several working days or
weekends to two months per annum.
These data suggest that there is considerable industry
demand for the expertise of university researchers, but
this demand is not (yet) accompanied by the full-time
job changes characteristic of the US-style “revolving
door” model of academia-industry employment [62].
Similarly, according to the 2011 Careers in Research On-
line Survey (CROS) of research staff in UK HEIs, the
proportion of staff reporting industry and business pla-
cements and secondments across the HE sector is still
low (5% and 7%, respectively), while other types of colla-
borations with industry are more prevalent (36% of the
total respondents) [63]. Consequently, in documenting
and assessing this area of impact, the absolute num-
ber and proportion of academic and research staff
who worked part-time in, or provided advice and
consultancy to, industry, their roles, and the time
spent working in or with industry need to be taken into
account.
Employment of post-doctoral researchers in industry
The Roberts Review of the supply of people with science,
technology, engineering and mathematics skills in the
UK acknowledged that post-doctoral and other contract
research staff (CRS) offer universities project-based
skills, staffing flexibility, new innovative approaches, and
other advantages [64]. Nonetheless, limited permanent
academic employment opportunities, not only in the
UK, but also internationally, cause concerns that CRS
may spend a long time moving from one temporary pos-
ition to another, to the detriment of their professional
development, career prospects, and quality of work and
life conditions [65]. For example, 14% of the research
staff surveyed in CROS 2011 reported having held five
or more different contracts of employment as research-
ers with their current institutions [63]. A further con-
cern arising from this situation is that highly-skilledgraduates would be less interested in pursuing research
careers [66-69]. Roberts argued against CRS remaining
on a series of short-term contracts for a long period of
time, and suggested improving CRS training in the skills
required either in an academic or industrial career and
that “in time. . . [the industrial career trajectory] should
come to be regarded as the ‘default option’ by CRS”
[64]. Therefore, whilst bearing in mind that industry de-
mand for higher degree graduates varies widely across
sectors and organisations [62], the employment of post-
doctoral researchers in permanent positions in industry
may be used as an indicator of the ability of universities
to provide CRS with skills and career development
opportunities (e.g. industrial placements and second-
ments) to pursue a corporate research career.
In trying to operationalise this indicator in Oxford, we
found no clear definition for post-doctoral research posi-
tions in the current human resources (HR) practices,
which seems to be a common limitation of the higher
education HR practices in many countries [68]. For this
reason, we examined data declared on the leaver’s form
to gather information on the destinations of leaving CRS
on grades 7 and 8 as a proxy for leaving post-doctoral
researchers. During the five-year census period, 1013
such CRS left clinical departments; the known destina-
tions of 762 CRS, who declared going into regular em-
ployment or study, are as follows:
 57% – education and research institutions in the UK
and overseas,
 22% – health services in the UK and overseas,
 9% – private industry/commerce or self-employed in
the UK,
 12% – other employment in the UK and overseas.
Another important limitation is the absence of any infor-
mation on whether the subsequent jobs of CRS are per-
manent or short-term. If a move into industry is
accompanied by a series of short-term contracts, then this
could be interpreted as a failure of the university in ques-
tion to help CRS develop skills for a more permanent car-
eer; vice versa, a move to another education or research
institution on a permanent contract could be interpreted
as a success. Given the lack of reliable data, developing a
clear, applicable measure of the employment of post-
doctoral researchers in industry seems problematic.
Concomitantly, these data draw attention to the move-
ment of physician-scientists and other highly-skilled
individuals who are trained to perform translational re-
search between universities and health services. Bridging
research and clinical practice by increasing the pool of
translational investigators is high on the agenda on both
sides of the Atlantic [70-72]. In the UK, for example, the
NIHR has established Academic Clinical Fellowships,
Table 2 Income from research grants and contracts in
clinical medicine by sponsor type, 2008/09
Sponsor type University of
Oxford
All UK HEIs
£M % £M %
Government 53.3 30.7% 558.9 41.5%
UK Research Councils, Royal Society
& British Academy
25.4 14.6% 222.5 16.5%
UK central government bodies/ local
authorities, health & hospital authorities
19.7 11.3% 282.0 20.9%
EU government bodies 8.2 4.8% 54.4 4.0%
Charity 89.0 51.2% 595.4 44.2%
UK-based charities
(open competitive process)
77.6 44.7% 454.7 33.8%
UK-based charities (other) 2.4 1.4% 78.3 5.8%
EU-based charities
(open competitive process)
0.2 0.1% 3.0 0.2%
Non-EU-based charities
(open competitive process)
8.7 5.0% 59.4 4.4%
Industry 20.3 11.7% 138.1 10.3%
UK industry, commerce & public
corporations
4.3 2.5% 84.0 6.2%
EU industry, commerce & public
corporations
1.2 0.7% 14.8 1.1%
Non-EU industry, commerce & public
corporations
14.8 8.5% 39.4 2.9%
Other 11.0 6.3% 54.4 4.0%
EU other 1.4 0.8% 5.9 0.4%
Non-EU other 9.6 5.5% 38.6 2.9%
Other sources 0.0 0.0% 9.9 0.7%
Total 173.6 100.0% 1,346.9 100.0%
Source: Higher Education Information Database for Institutions (heidi), 2010.
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ician Scientist Awards to promote integrated academic
and clinical careers at the pre-doctoral, doctoral, and
post-doctoral levels [73]. The efforts of universities and
their partner teaching hospitals to increase the pool of
translational investigators can, thus, be assessed by
measuring the number of such awards.
Creating new businesses, improving the performance
of existing businesses, or commercialising new products
or processes
Research contracts and income from industry
Whilst different types of research can have impact on the
economy, the Cooksey Review of UK health research
funding concluded that more opportunities to create add-
itional health and wealth benefits from research lie in
translational and applied research [74]. The review recom-
mended that, while sustaining the current funding levels
for basic science, “future increases in funding should be
weighted towards translational and applied research until
a more balanced portfolio is achieved” [74]. Empirical
studies suggest that scientists with industry funding con-
duct more applied research and, contrary to a popular
assumption that industry funding negatively affects trad-
itional scientific outputs such as publications, they also
produce more scientific publications than scientists with-
out industry funding [75,76]. Therefore, research contracts
and income from industry can be used as an indicator of
potential health and wealth benefits for the economy, and
an increased level of industry funding may also positively
affect the traditional scientific outputs.
According to the Higher Education Statistics Agency
(HESA), income from research grants and contracts in
clinical medicine from industry in 2008/09 was higher in
Oxford (£20.3 million) than in any other UK HEI except
Imperial College London (£26.1 million); it accounted
for 11.7% and 10.3% of external research income in
Oxford and all UK HEIs respectively (Table 2) [52].
While research income from industry is a useful indica-
tor, it does not allow assessment of the potential health
and wealth benefits of the overwhelming majority of
clinical medicine research in UK HEIs, which is funded
by the public either through government agencies or
charities. Yet, the pharmaceutical industry is highly
dependent on publicly-funded research, in particular
basic research [77]. US studies found that 31% of drugs
and medical products could not have been developed
(without substantial delay) in the absence of recent aca-
demic research [78], and that 79.1% of the papers cited by
US industry drug and medicine patents were outputs of
publicly-funded academic science [79]. Most citations in
patents are journal references and may be used to develop
robust bibliometric indicators [80]. Similar to the use of
bibliometric analyses of highly-cited publications by theNIHR to support the procurement of Biomedical Research
Centres in England [81], HEFCE and other research fun-
ders can use bibliometric analysis of citations in patents to
assess the contribution of publicly-funded clinical medicine
research to innovations in industry.
Collaborative research with industry measured through
co-authored outputs
Measuring co-authored publications is a well-grounded,
although not comprehensive, way of assessing collabora-
tive research with industry. There is evidence from the
US that university-industry collaborations tend to be
driven by industry’s agendas and that the resulting co-
authored publications are less basic and more applied
than universities would produce otherwise [82]. More-
over, empirical studies from different countries suggest
that co-authored publications are positively associated
with researchers’ productivity in terms of the number of
publications and citations, but there is no conclusive evi-
dence on whether co-authored publications are more
likely to appear in journals with higher or lower impact
factors than university-only papers [82-84]. However,
there is evidence to the effect that measuring co-
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assessing university-industry collaboration. For example,
in the case of a Swedish medical university both industry
funding and co-authorship indicators were shown to
provide incomplete results [85], and a study of multi-
disciplinary research teams in Germany concluded that
co-authorships could account for about half of the actual
collaborations [86]. On the whole, analysing co-authored
publications can be a useful, but by no means exhaust-
ive, way of assessing university-industry collaboration.
In Oxford, 30% of respondents to the impact assess-
ment survey reported co-authoring one or more publica-
tions with colleagues from industry over the five-year
census period (averaging 3.5 publications per respond-
ent). A number of respondents also mentioned industry-
funded publications with only academic authors, and
further publications acknowledging industry funding.
Furthermore, our analysis of administrative records
revealed collaborative relationships with industry that
were not necessarily accompanied by industry funding
or co-authored publications, but could be accounted for
by less conventional indicators such as memoranda of
understanding, confidentiality agreements, collaboration
agreements, data/material transfer agreements, and vis-
itor agreements. Hence, it can be suggested that impact
narratives should include additional indicators, such as
those mentioned above, in order to capture a fuller
range of collaborative relationships with industry.
Income from intellectual property
The large-scale exploitation of intellectual property by uni-
versities is relatively new to the UK. The right of first re-
fusal on the commercialisation of publicly-funded research,
held for many decades by the British Technology Group,
was only rescinded in 1985. As a consequence, universities
gained direct control over, and exploitation of, their intel-
lectual property, with a view to generating income for
themselves and contributing to national wealth creation
[87]. Not with standing conflicting views on whether com-
mercialisation can harm or promote basic research and
education [88], encouraging and providing universities with
funding to engage more actively in the exploitation of intel-
lectual property has consistently been the government’s
policy [58,89-91]. A 2009 HEFCE report concluded that
there was strong support for knowledge exchange in HEIs
and that it was increasingly seen by HEIs as complemen-
tary to their traditional research and education activities
[92]. However, the report stated that revenues from intel-
lectual property represented a very small proportion of in-
come from knowledge exchange [92]. Even in the US, with
its long history of university technology transfer, revenues
from intellectual property are rather small compared to re-
search expenditure – most universities break even or make
only a small amount from their investment in technologytransfer activities [93]. Moreover, the total revenue from
technology transfer in US universities and research hospi-
tals is “dominated by a few very large royalties from fewer
than 1% of total patents” and is uneven over time:
“pharmaceutical royalties are high – but very rare,” and
“equity cash-ins from spin-outs are only occasionally large,
and are one-time” [93].
Oxford academics were already entrepreneurial in the
1950s, but it was not until the establishment of the univer-
sity’s technology transfer office in 1988, Isis Innovation,
that Oxford became “arguably the UK’s most entrepre-
neurial university” [94]. Isis Innovation helps academics
and researchers commercialise their work through patent-
ing and licensing, material sales, spin-out companies, and
consulting. Between 2004/05 and 2008/09, the total pro-
ject income of Isis Innovation was £9.8 million, 50% of
which may be attributed to clinical medicine. Precise attri-
bution is somewhat problematic, because many deals were
multidisciplinary (involving clinical, pre-clinical, and bio-
engineering departments) and the current information
system does not allow accurate dissection of the existing
data in relation to academic departments. Given that in
this five-year period Oxford’s clinical medicine research
expenditure amounted to £612.9 million [52], intellectual
property return on research expenditure was approxi-
mately 0.8%. Overall, the total income from intellectual
property is a useful indicator, but currently it is problem-
atic to attribute it accurately between multiple depart-
ments and it represents only a small percentage compared
to research expenditure. It seems more expedient to assess
it on the level of the HEI as a whole and in individual
subject-groups use case studies only of the most successful
commercialisation activities.
Success measures for spin-out companies
Technology transfer through spin-out companies has
advantages over licensing when the nature of new technol-
ogy may not be easily patented and when universities seek
a greater return on their intellectual property in the long
run [95]. For all that, spinning out university companies is
rather resource-intensive, in terms of both funding and the
inventor’s time. The Lambert Review pointed out that, due
to the ready availability of funding for high-tech start-ups
and an undue emphasis on spin-outs as a source of em-
ployment, too many university spin-outs were being cre-
ated in the UK compared to North America, including
some of low quality [58]. Lambert suggested shifting the
balance of commercialisation activities towards licensing
and concentrating on high-quality spin-outs, as measured
by their ability to attract external private equity [58]. In
light of this, together with growth in revenue or numbers
of employees, as proposed by HEFCE, external private
equity backing can be taken as an important success meas-
ure for spin-out companies.
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companies and attracts more investment than any other
UK university [96]. In doing so, it tries to replicate the
success of PowderJect Pharmaceuticals – a vaccine, drug
and diagnostics delivery company spun out from the
university in 1993 and acquired ten years later by Chiron
Corporation for $800 million [97]. During the census
period, Isis Innovation supported the creation of 25
spin-out companies, of which 8 related to clinical medi-
cine in the following areas [98]:
 Celleron – developing targeted cancer medicines;
 TΔS – developing ketone bodies as medical foods to
increase physical and mental performance;
 Particle Therapeutics– needleless delivery of
therapeutic molecules across the skin;
 Cytox– pre-symptomatic diagnosis of Alzheimer's
Disease;
 Clinox– provider of phase I/II trials in oncology;
 Oxford BioDynamics– detection of aberrant gene
expression (prognosis and diagnosis);
 Oxford-Emergent TB Consortium –joint venture
with Emergent BioSolutions to develop tuberculosis
vaccine candidate, MVA85A;
 Organox – portable device to preserve livers for
transplantation for up to 3 days.
During the census period, these spin-out companies
employed a small number of people (on average 18 people
per annum) and generated no income from sales. Never-
theless, they raised a total of £15.7 million in external pri-
vate equity, indicating investor confidence in future
revenue growth. They also spent a significant proportion
of their expenditure on R&D in universities or technology
consultancy companies, contributing to job creation in
these sectors. As one respondent to the impact assessment
survey argued, the success of spin-out companies is not
measurable over a five-year period: “our 2 spin out com-
panies took, in one case 7 years, and in the other more
than 10 years, before they [could] realise their full value by
either bringing products, such as new drugs, to market or
by being successfully sold or by going public”. It can, thus,
be argued that the success of spin-out companies should
be evaluated over a longer period of time and that quality
measures, such as the ability to attract external private in-
vestment, should also be taken into account.
Patents granted/licences awarded and brought to market
Patenting and patent licensing is not as resource-
intensive as spinning out companies, but seeking to in-
crease the levels of patenting and licensing may lead to
unintended consequences. For example, Henderson
et al. argued that the Bayh-Dole Act, which incentivised
US universities to patent, resulted in the decline of thequality of university patents, as measured by citations in
subsequent patents [99,100]. Others demonstrated that in-
creasing the number of inventions, for which patent appli-
cations were made and licences sought, reduced the
average “yield” of these commercialisation activities [101].
Also, there are concerns that excessive proliferation of in-
tellectual property rights may deter innovation [102], and
that misconceptions in the value of intellectual property
may inhibit collaboration with industry [103]. Finally, be-
yond a certain level, higher levels of patenting are nega-
tively associated with academic productivity in terms of
publications [104] and their “basicness” [105]. For these
reasons, patent numbers may be noisy indicators of know-
ledge transfer and commercialisation. In order to minim-
ise the negative unintended consequences of excessive
patenting, it is important to take into account the quality
of patents, which can be measured by licences or by cita-
tions in subsequent patents. Licences are an appealing
measure of quality because they indicate the economic
value of patents and they are enforced by the competing
interests of licensors and licensees [106]. Citations in sub-
sequent patents are indicative of the technological import-
ance of the antecedent patent, i.e. they draw on the
knowledge embodied in the antecedent patent, and/or
they may indicate that the antecedent patent had opened
up a new field of inventive activity [100].
During the financial years 2004/05 to 2008/09, Isis
Innovation filed a total of 293 new patent applications from
university researchers in Oxford, of which 63 were based
on disclosures from clinical medicine departments. Within
the same period 276 licence deals were completed, includ-
ing 61 that were related to projects derived from clinical
medicine disclosures. There are no comparative data for
patents and licences in clinical medicine, but in life sciences
in general Oxford publishes more patents than any other
university in the UK [96]; and overall Isis Innovation files
more international patent applications to the World Intel-
lectual Property Organization under the Patent Cooper-
ation Treaty than any other university in Europe [107].
Given that there is a significant variability between UK uni-
versities in research power and commercialisation activity,
it is useful to take into account universities’ research power
when comparing the absolute number of patents or
licences [96]. Moreover, given that the absolute number of
patents does not provide information about their quality, it
would be more effective using this measure in combination
with additional measures, such as income from licencing
and citations in subsequent patents.
Attracting R&D investment from global business
Research income from overseas business
The globalisation of R&D has grown substantially over
the past decades [108] to the effect that increasingly
R&D is being outsourced to Asia, particularly China and
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of technological advances worldwide, but raises concerns
about the future of the domestic knowledge base in
OECD countries and the competitiveness of their econ-
omies [109]. In addressing such concerns, the UK’s na-
tional health research strategy, Best Research for Best
Health, aims “to make the UK the best place in the
world for health research, development and innovation”
[30]. Empirical research has found a positive association
between the productivity of academic research in host
countries (as measured by the number of publications)
and the level of foreign R&D investment, and that aca-
demically stronger countries attract companies with a
stronger science orientation in their R&D activities
[110]. It follows that research income from overseas
companies may be indicative of the contribution of a
university’s research to both the competitiveness of the
domestic economy and global economic growth.
In 2008/09, UK HEIs attracted £54.2 million of re-
search income from EU and other overseas industry, of
which Oxford accounted for £16 million (Table 2).
While the percentage of non-EU overseas industry fund-
ing in Oxford is more than twice as high as in all UK
HEIs combined, the percentage of EU industry funding
in Oxford is lower (Figure 2). Overall, Oxford attracts
significantly more R&D investment from global business
than the average UK HEI, as 78.9% of Oxford’s industry
research income comes from overseas industry.
Better-informed public policy-making or improved public
services
Changes to legislation/regulations/government policy
It has been argued that “the use of research knowledge
to inform decision-making, not a change in health sta-
tus, constitutes the most important generic measure of
the impact of research that can be assessed routinely”Figure 2 Income from research grants and contracts in clinical
medicine from industry, 2008/09. Source: Higher Education
Information Database for Institutions (heidi), 2010.[111]. Yet, the attribution of policy changes to particular
research projects or funding is a methodologically-
challenging and research-intensive task [112]. A recent
review of research impact on policy concluded that “the
interests of various stakeholders such as politicians, pub-
lic servants, religious groups, pharmaceutical and diag-
nostic companies, and health professionals may often
run counter to the introduction of new research find-
ings, thus, affecting policy making, budgeting, and im-
plementation” [113]. Moreover, given the collective
nature of decision-making in democratic societies, it is
challenging to attribute changes in legislation, regula-
tion, or government policy to certain teams or indivi-
duals. As Weiss argued as early as 1979, “it probably
takes an extraordinary concatenation of circumstances
for research to influence policy directly” [114]. It follows
that, for the most part, the assessment of research im-
pact on policy requires the triangulation of data from a
number of stakeholders using qualitative methods and a
case study approach [113,115].
In Oxford, 9% of respondents to the impact assessment
survey reported influencing changes to legislation, regula-
tions, or government policy on the national, European, or
international levels. The range of their activities mainly
concerned the provision of thought leadership and advice
to various governmental, professional, and advisory bodies.
For example, one respondent mentioned a secondment to
the Department of Health as a national clinical director to
write and implement government policy for a major clin-
ical service. In another example, a respondent mentioned
direct contacts with the World Health Organization, in
his/her role as president of an international professional
society, leading to updates to guidelines for a complex area
of practice and research. Other respondents also men-
tioned instances of their papers being used as evidence
during public policy deliberations, or themselves par-
ticipating in policy advocacy campaigns. It is impor-
tant to note that several respondents were sceptical
about the feasibility of attributing policy changes to
one’s research-based activity, and one respondent ad-
mitted to not knowing how to prove that his/her policy
advocacy had contributed to policy change. A further limi-
tation arises from the fact that assessing only documented
influence on changes to legislation and regulation (e.g., on
the basis of references made to research outputs in policy
documents) will overlook the more complex, qualitative
aspects of academics’ participation in the democratic de-
liberation and implementation of public policies. Taking
all these into account, it seems to be more inclusive and
less burdensome to assess researchers’ participation in
public policy processes, for example, through provision of
advice and leadership, rather than attempting to separate
out the contribution of specific research in achieving
changes to legislation and regulation.
Table 3 Media coverage of scientists from clinical
medicine departments, 2009
Type of media Stories
n %
UK & international press 390 62.3%
UK & international online news* 123 19.6%
UK radio 60 9.6%
UK television 53 8.5%
Total 626 100.0%
*Unknown whether a story appeared in hard copy as well.
Source: Press & Information Office, University of Oxford.
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Universities can play an important role in ensuring that
government policies “are forward-looking and shaped by
the evidence rather than a response to short-term pres-
sures” [116]. University academics generate an evidence
base for public policy [117] and can facilitate the passage
of new research knowledge into the evidence base of
concrete policies. Their participation on public policy/
advisory committees may smooth that transition and,
thus, can be regarded an indicator of impact. Taking into
account the multi-stakeholder nature of public policy-
making in democratic societies, this indicator includes not
only public policy/advisory committees of government
agencies, but also those of supranational organisations,
professional bodies, charities, and other stakeholders
involved in public policy-making.
In Oxford, 42% of respondents to the impact assess-
ment survey reported participating on public policy/
advisory committees of various UK, overseas, and supra-
national organisations, including the World Health
Organization, the European Space Agency, UK Depart-
ment of Health and other government agencies, UK par-
liamentary committees, political parties, professional
associations, medical charities, universities, and schools.
The significance of these roles ranged from elected or
appointed senior leadership positions to ordinary com-
mittee membership or ad hoc advisory roles. Import-
antly, several respondents suggested that participation
on the advisory committees of charities should be
included in impact assessment, although they had reser-
vations about the additional burden of work that keeping
full, accurate records of all these activities would require.
One respondent noted:
“I sit as a trustee of probably up to 12 charities, most
of which have something to do with medical research. I
think that sort of contribution is at least as important as
contributions made to government activities. [However]
I think it would be intolerable to have to keep a detailed
account of all such activities and how would they be
ranked relative to each other.”
Influence on public policy debate
UK scientists see the news media as having a significant
impact on public debate and many regard speaking to
the media as the most effective method of communicat-
ing with the public and influencing policy-makers [118].
Moreover, a survey of interactions with the mass media
among researchers in France, Germany, Japan, the UK,
and the US concluded that “the scientists most involved in
these interactions tend to be scientifically productive, have
leadership roles, and. . . that they perceive the interactions
to have more positive than negative outcomes” [119].
Nonetheless, there may be a bias in reporting on the side
of both the mass media and research institutions. Mediainterest in research may be linked to profound concerns
about the evidence base for public policy, or with genuine
interest in new knowledge, but it also feeds on what a re-
spondent to a recent study called the “scientific entertain-
ment value” of research [112]. A UK study suggested that
“newspapers underreported randomised trials, emphasised
bad news from observational studies, and ignored research
from developing countries” [120]. A US study showed that
news stories about new medical interventions are often in-
accurate, imbalanced, or incomplete, and that as a result
“may have a profound—and perhaps harmful— impact on
health care consumers” [121]. But it is not only journalists
who may be over-enthusiastic about weak science: press-
releases by US academic medical centres themselves may
have “a tendency to overstate the importance and down-
play (or ignore) the limitations of research” [122]. For this
reason, any media impact indicators should take into ac-
count not only the number of citations and appearances,
but also their quality, and should be used with caution.
In Oxford, 42% of respondents to the impact assessment
survey reported appearing in the local, national, or inter-
national mass media during the five-year census period.
Although no direct comparison is possible, this may be
lower than implied by an earlier survey of epidemiology
and stem cell researchers in the top five R&D countries
for these fields, of whom 69% had been involved in inter-
actions with the mass media in the last three years [119].
The range and magnitude of media impact in the context
of this study can be assessed using data from the univer-
sity’s Press & Information Office. For example, Table 3
shows the coverage of scientists from clinical medicine
departments in conventional media in 2009. In addition,
since October 2008, university clinical scientists have been
able to disseminate their research through the iTunes U
website, which in 2009 carried 6 free-to-download pod-
casts relevant to clinical medicine: Cancer, Cancer in the
Developing World, Childhood Diseases, Clinical Trials in
Resource-Limited Settings, Pharmaceutical Industry, and
Vaccine Research [123]. The number of downloads for
such podcasts can be obtained from Apple Inc. and com-
pared with other universities.
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coverage does not necessarily lead to influence on public
policy debate. Only 12% of respondents to the impact
assessment survey reported perceptions of influencing
public policy debate. Similar to some of the previous
indicators, influence on public policy is a subjective indi-
cator, and media coverage is only a weak measure of it.
An important aspect of influencing public debates can-
not be captured by such indicators: the potentially trans-
formative influence of research on public discourses
about policy and clinical practice includes shaping the
ways in which such discourses frame problems and their
solutions, and slowly changing the language in which
they describe the social and physical worlds.
Improved patient care or health outcomes
Research income from the NHS and medical research
charities
Competitively-awarded NHS and charity funding is pre-
dicated on the high quality of research and benefits for
patients. The NHS Constitution puts research at its core
because “[r]esearch enables the NHS to improve the
current and future health of the people it serves” [124].
Likewise, medical research charities aim to fund research
that is important for the advancement of medical care
[125]. Until the creation of the NIHR in 2006, NHS
R&D funding was allocated to sustain the level of activ-
ity in large teaching hospitals and it is argued to have
been “far more a product of history, politics and prag-
matic judgments than any rational analysis” [126]. Fol-
lowing the creation of the NIHR, the majority of NHS
R&D funding is now awarded competitively to NHS/uni-
versity partnerships on the basis of peer review and
bibliometric indicators [81]. Medical research charities
have long been using peer review and research output
indicators to allocate their research funding. In the run-
up to the previous Research Assessment Exercises they
urged government, the NHS and universities “to favour
peer-reviewed charity research above funding that is not
awarded competitively” [125]. Crucially, medical re-
search charities aim to allocate research funding in order
to achieve the greatest impact, and in fact they cham-
pioned the idea of assessing the long-term benefits from
health research in the UK [25]. Yet, there is evidence
that competitively-awarded NHS or charity research
funding does not necessarily achieve impact. An exten-
sive assessment of the impact of the NHS Health Tech-
nology Assessment Programme found that some of its
projects achieved virtually no societal or economic im-
pact [127]. It remains to be seen what proportion of
competitively-awarded research funding predicated on
impact actually achieves impact and which NHS bodies
or medical research charities are most successful in
funding research that achieves greater impact.Although the validity and reliability of using compe-
titively-awarded research funding as a proxy indicator of
impact requires further investigation, our study suggests
that it is feasible to collect the required data and that
this can be done with minimal burden on academic staff.
HEFCE has recently recognised the competitive nature of
NHS research funding, and to this effect the Higher Edu-
cation Statistics Agency (HESA) is tasked with reporting it
specifically alongside other competitively-awarded funding
[34]. Charity funding is the most important source of ex-
ternal research income in UK HEIs and its overwhelming
majority is awarded competitively. In 2008/09, charity
funding accounted for 51.2% and 44.2% of clinical medi-
cine external research income in Oxford and all UK HEIs
combined respectively (Table 2). Since the introduction of
competitive mechanisms to allocate NHS R&D funding,
NHS/university partnerships in Oxford have been success-
ful in obtaining major awards, such as a NIHR Com-
prehensive Biomedical Research Centre and NIHR Bio-
medical Research Unit. But if we look at the percentage of
research income from “UK central government bodies,
local authorities, and health and hospital authorities” in
Table 2, which mainly reflects research income from the
NHS, it is still almost twice as low in Oxford (11.3%) as in
all UK HEIs combined (20.9%).
Measures of improved health services
In the UK, up to 5%-10% of the medical workforce is
made up of clinical academics – university employees
who, in addition to their teaching and research duties,
have honorary contracts with the NHS as practicing doc-
tors [128]. As of 2009, there were over 125 full time
equivalent (FTE) university-employed clinical academics
in Oxford, who represented 4% of the clinical academic
workforce in the UK [128]. They play a leading role in
translating research from bench to bedside and make a
significant contribution to the delivery and improvement
of health services, especially those that are highly specia-
lised and technology-intensive. Respondents to the im-
pact assessment survey stressed the link between
research and their own professional development, enab-
ling state-of-the-art care for patients, which would
otherwise take years to be established through changes
to clinical guidelines. As we argued elsewhere, a strong
link between practice, as praxis, and research involves
their “organic” synergy in practitioners’ everyday profes-
sional lives, “which is more than having effective traffic
of information between two otherwise discrete commu-
nities and activities” [129].
Importantly, a number of respondents commented on
impact assessment as an opportunity for better recogni-
tion of the clinical aspects of their work. They argued
that the conventional indicators of research output dis-
advantaged clinical academics, compared to full-time
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time for basic research and better chances to publish it
in journals with high impact factors. An anaesthetist,
who was dissatisfied that in the previous RAE his/her
specialty was judged solely on the basis of research out-
puts, commented:
“If these [impact] measures are introduced. . . it will be-
come impossible for either universities locally or HEFCE
nationally to ignore the clinical contributions of anaesthe-
tists and focus narrowly upon research outputs.”
Overall, 13% of respondents reported improving health
services, mainly in their local area. The range of impacts
reported included: improving diagnostics and drug re-
sponse prediction, fulfilling previously unmet clinical
needs, making highly-specialised services more access-
ible for the local communities, applying new recovery
and rehabilitation strategies, and reducing waiting times
and treatment costs. Given the wide range of impacts
reported, it does not seem feasible to have one standar-
dised measure of improved health services, and so, like
in other practice-oriented fields, case studies can be a
useful method to capture such impacts [130]. Nonethe-
less, some standardised measures could be used as a
proxy for the impact of universities on the delivery of
health services, e.g. the number of university-employed
clinical academics, their time (programmed activities)
devoted to clinical work, and their translational research
leadership and esteem as measured by NHS Clinical Ex-
cellence Awards and NIHR Senior Investigator Awards.
Changes to clinical or healthcare training, practice or
guidelines
Even though individual clinicians can adopt research find-
ings directly from academic publications, mass adoption at
a national or international level is usually facilitated by clin-
ical guidelines and other evidence-based recommendations.
Clinical guidelines, such as those produced by the National
Institute for Health and Clinical Excellence (NICE), aim to
improve the quality of healthcare in the UK by providing
clinical recommendations based on the best available evi-
dence [131]. Consequently, references to research in clinical
and practice guidelines can be used as indicators of the
likely application or adoption of research findings in clinical
practice [132]. Although a citation in clinical guidelines
does not guarantee an impact on health, it demonstrates a
peer perception of research utility and can be considered as
an intermediate outcome [26]. Research by the Wellcome
Trust, the Medical Research Council (MRC), and the NIHR
demonstrated the feasibility of employing conventional
bibliometric analysis of research papers cited on clinical
guidelines to assess the impact of biomedical research on
healthcare policy and practice [24,26,133].
In Oxford, 20% of respondents to the impact assess-
ment survey reported that their work had resulted inchanges to clinical or healthcare training, practice or
guidelines at a local, national, European, or international
level. These reports were supported with evidence both
of output (references in published guidelines) and of
process (direct participation in the production of guide-
lines).The majority of respondents mentioned that their
research had been cited by, or that they participated in
the working groups or committees of, the NICE, UK
Royal Colleges, international professional associations,
the World Health Organization, and other relevant bod-
ies. A number of respondents also mentioned that their
research was cited in NHS National Service Frameworks
and Strategies. Inclusion in use-oriented systematic
reviews, such as Cochrane Reviews, which screen studies
for quality and relevance, was mentioned as another
possible measure of impact. Whilst clinical guidelines,
official recommendations, and systematic reviews lend
themselves well to bibliometric analysis, some other
types of evidence mentioned by respondents (e.g. leading
on a new MSc course for practising physicians, develop-
ing a section of the NHS Evidence web service, or pro-
posing a new classification system for an infectious
tropical disease) favour case studies. A case study
method may be appropriate for claims about impacts on
training and professional standards, accreditation frame-
works, curriculum and teaching materials and textbooks,
and pedagogical approaches in medical education. For
these reasons, a mixed method approach, encompassing
both bibliometric analysis and case studies, can be used
to assess this area of impact.
Development of new or improved drugs, treatments or
other medical interventions; numbers of advanced phase
clinical trials
The clinical trial in human beings is a valid and apt indi-
cator for the development of medical interventions be-
cause currently it is “the preferred method in the
evaluation of medical interventions” [134], representing
“a key research activity with the potential to improve the
quality of health care and control costs through careful
comparison of alternative treatments” [135]. Moreover,
experimental animal models and other pre-clinical stud-
ies can be assessed on the basis of whether they have
progressed to clinical trials, and the latter can be
assessed on the basis of the benefits associated with each
phase of clinical trials. Even though some medical inter-
ventions can be difficult to classify, clinical trials are
conventionally divided into phases I-IV. Phase I trials are
generally designed as pharmacology studies; phase II trials
are therapeutic exploratory investigations; phase III trials
are assessments of the effectiveness of the new interven-
tion; and phase IV trials are investigations into uncommon
adverse effects of the new intervention [134]. Given the
strategic intention of the NIHR to increase the number of
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health benefits of participating [30], the number of partici-
pants in clinical trials is also an important indicator for
the development of medical interventions.
The University of Oxford runs one of the UK’s largest
clinical trials programmes in collaboration with many
academic health centres in the UK and overseas. There
are eight clinical trials units that have been awarded UK
Clinical Research Collaboration (UKCRC) Registration,
which recognises their capability to coordinate multi-
centre clinical trials to a required standard [136]. During
the census period, the university sponsored or partici-
pated as a research site in 140 clinical trials involving
154,888 participants (Table 4). According to the impact
assessment survey, 32% of respondents reported contrib-
uting to the development of new or improved drugs,
treatments or other medical interventions. As one re-
spondent noted, however, it is important to give appro-
priate credit to early-phase translational research and
basic science, which underpin advanced phase clinical
trials with the most immediate patient benefits:
“impact assessment needs to consider carefully the
various stages of translational research so as to award
credit correctly to those who have devised and brought
to clinical evaluation new interventions, rather than giv-
ing disproportionate credit to those who undertake late
stage evaluation of technologies invented by others.”
Changes to public behaviour
There is a growing recognition in medicine and public






I II III IV N/A
Cancer 7 1 4 1 1 27314*
Cardiac/circulation 8 1 4 3 56335
Diabetes 7 3 4 16350*
Infectious disease 25 19 3 1 1 1737*
Neo/perinatal 4 1 2 1 7220
Nervous system 2 2 312
Obstetrics/gynaecology 2 1 1 240
Paediatrics 17 8 2 6 1 5510
Public health/primary care 1 1 180
Psychiatry 8 1 2 4 1 1853
Renal 2 1 1 848
Respiratory medicine 4 1 1 2 686
Tropical medicines 53 9 15 8 7 14 36303*
Total 140 29 31 24 32 23 154888
*incomplete data.
Source: Clinical Trials and Research Governance Team, University of Oxford.effects lessened by making and maintaining changes to
public behaviour, and that demands and responsibilities for
such changes should be placed not only on the individual,
but also on the health system, the community, and the so-
cial and political context [137]. It is a valid expectation on
the part of research funders that the medical research com-
munity should promote health-enhancing changes to pub-
lic behaviour. At the same time, the measurement of health
behaviours is challenging [137], and so is the attribution of
behavioural change to specific research findings [25].
In Oxford, 7% of respondents to the impact assess-
ment survey reported, or expressed hope, that their work
had resulted in health-enhancing changes to public be-
haviour. For example, one respondent assessed that
since the implementation of the National Stroke Strategy
and the establishment of a new academically-led Stroke
Unit in the Oxford John Radcliffe Hospital:
“[stroke] has become an emergency treatment, patients
are arriving much more quickly and the public attitude
towards stroke has changed insofar as patients now
recognize it as a medical emergency.”
Another respondent cited an increased referral rate
from UK regions and Ireland to demonstrate a greater
awareness of a new life-extending treatment:
“by initiating the FOXFIRE national clinical trial,
patients and relatives are seeking the availability of ‘radio-
embolisation’ treatment at centres such as Oxford.”
Yet others cited activities, which they hoped would
change health-risk behaviours:
 “I would hope that our work on the adverse effects
of obesity on heart and arteries has led to increased
awareness of obesity as a risk factor”
 “[I was a] Member of Tobacco Control Forum that
advised on legislation on smoking ban in restaurants
and public houses”
 “I have participated in the Cancer Research UK
SunSMART campaign that aims to increase public
awareness of exposure to sunlight and the risks of
developing skin cancer.”
Given that it is extremely challenging to compare such
diverse behavioural changes and verify to what extent
they are attributable to specific research, case studies,
complemented by standardised measures of health out-
comes, can be used to describe such changes, explore
their connections with underpinning research, and esti-
mate their potential health benefits. For more robust
conclusions, however, more specialised and adequately
resourced impact evaluation studies would be required.
Measures of improved health outcomes
Research can lead to improved health outcomes through
many different pathways, including improvements in
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ing, development of new drugs and treatments, and
changes to public behaviour as discussed above, but also
through the development of new methods to measure
health status [6]. Despite the multitude of pathways and
disease states, there are standardised measures for asses-
sing health outcomes, such as Quality Adjusted Life
Years (QALYs), Disability Adjusted Life Years (DALYs),
Health Adjusted Life Expectancy (HALE), and Medical
Outcomes Study 36-item Short-Form Health Survey
(SF-36) that can be used in research impact assess-
ment [6,18,25]. The key advantage of such measures
is that “they serve as a common metric to allow fun-
ders to assess the value of an investment across dis-
ease states” [18].
In Oxford, 17% of respondents to the impact assess-
ment survey reported that their work had directly or in-
directly improved health outcomes in the UK and/or
overseas. The range of suggested improvements included
reduction in mortality, morbidity, and accumulated dis-
ability; improvements in the quality of life of patients
and their carers; as well as the development of new
disease-specific patient reported outcome measures
(PROMs). For all that, none of the respondents were
able to provide quantified outcome measures and many
expressed concerns that it was difficult to attribute, ver-
ify, quantify, and meaningfully compare improvements
in health outcomes across various diseases and popula-
tions. For example, how does clinical islet transplant-
ation leading to insulin-independency and reversal of
life-threatening hypoglycaemic unawareness in UK
patients, cited by one respondent, compare to research
on the national introduction of the pneumococcal vac-
cine in the Gambia, cited by another respondent? These
responses suggest that there is a need for research fun-
ders and the medical research community to develop
uniform guidelines for the identification of the popula-
tions who can benefit from various interventions, the
level of benefit, and the extent of implementation. Pro-
vided such guidelines are developed, the standardised
measures of health outcomes such as QALYs, DALYs, or
HALE can be employed by universities to make initial
estimates of health benefits, which may be subsequently
validated by research funders and used in conjunction
with case studies.
Cultural enrichment, including improved public engagement
with science and research
Increased levels of public engagement with science
and research
Public engagement, or science communication and pub-
lic understanding of science, as it is also known, is an in-
clusive term that refers to “the many ways in which
higher education institutions and their staff and studentscan connect and share their work with the public.”
[138]. The Concordat for Engaging the Public with Re-
search, which is signed and supported by major UK fun-
ders and stakeholders, recognises “the importance of
public engagement to help maximise the social and eco-
nomic impact of UK research” and suggests that “UK re-
search organisations have a strategic commitment to
public engagement” [139]. Likewise, the NIHR has a
strategic commitment to involving patients and the pub-
lic in all stages of NHS R&D, because it sees such en-
gagement as leading “to research that is more relevant
to people’s needs and concerns, more reliable and more
likely to be put into practice”[30]. For many years, vari-
ous research funding organisations, including charities,
have been running schemes of additional funding for
public engagement and outreach projects; the amount
and number of such awards may be a proxy for univer-
sities’ interest in public engagement activity.
At the same time, a study by the Royal Society found
that, in general, scientists did not prioritise public en-
gagement activities because of the need to spend more
time on research [140]. They did, however, express will-
ingness to engage more with the public and believed that
including public engagement in the Research Assess-
ment Exercise would provide an incentive to do so
[140]. While there is a choice of possible indicators of
institutional interest and investment in public engage-
ment and outreach activity, and adequate measures and
proxies can be developed, they are of limited use in cap-
turing the outcomes of such activities and their actual
benefits for the populations concerned [112]. These lim-
itations were powerfully stated in the report of a recent
study of 15 European countries, which showed that
“analysis and evaluation of PE [public engagement] ac-
tivities is still underdeveloped, lacking robust and shared
indicators of output and performance” [141]. Whereas
standardised surveys can be used successfully to collect
data about public engagement activity [118,140,141],
there remains a challenge for HEFCE to develop rigor-
ous methods to assess their quality and outcomes – both
for the purpose of the REF and to support those univer-
sities who wish to promote it on the institutional level.
In Oxford, 54% of respondents to the impact assess-
ment survey reported participating in patient and public
involvement activities during the five-year census period.
Although no direct comparison is possible, this may be
lower than implied by national, multi-disciplinary stud-
ies. For example, the 2006 Royal Society survey found
that 74% of scientists and engineers in various disci-
plines, including clinical medicine, had participated in
science communication or public engagement activities
in the year prior to the survey date [140], while a 2000
survey by the Wellcome Trust and MORI found that
52% of clinical biomedical scientists had participated in
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and public involvement activities reported in this survey
were very diverse in nature, including acting as a Science
and Engineering Ambassador, giving public lectures and
talks to patient groups, communicating with patients
and clinical trials volunteers, acting as a patron to a
patient support group, participating in the NIHR Bio-
medical Research Centre (BRC) Open Days, collabora-
ting with a Wellcome Trust Artist-in-Residence, being
interviewed by a journalist, maintaining a public web-
site, engaging with policy-makers and NGOs, working
with science centres and museums, organising work-
shops for pupils at local schools, and judging various
competitions.
Given the many ways in which public engagement ac-
tivity manifests itself, it is challenging to compare them
in a standardised manner. For example, one respondent
mentioned “public events to raise awareness of issues
surrounding stem cell biology: World Economic Forum
Annual Meeting, Davos. . ., [local schools], Witney.”
How does researchers’ engagement with global leaders
in Davos compare with their engagement with school-
children in the local community, and how does one esti-
mate the value to the local community of world research
leaders engaging with schoolchildren? Moreover, because
the majority of respondents participated in several
events every year the burden of collecting data about
public engagement activity may be substantial. As one
respondent – whose involvement with the British Sci-
ence Association over several decades had led to many
developments, including the creation of a science com-
munication award – remarked:
“It is really too much to expect that one should keep a
detailed account of all such activity and would indeed be
inhibiting of such activity.”
In order to minimise the burden and standardise indi-
cators, HEFCE can draw on the Wellcome Trust and
Royal Society studies to develop a discipline-specific
public engagement survey, which can be administered as
part of the annual HEFCE Higher education-business
and community interaction survey (HE-BCI).
Improved social welfare, social cohesion or national
security
Measures of improved social equity, inclusion or cohesion
There are several important ways in which universities
can improve social equity, inclusion, and cohesion. Uni-
versities can enhance diversity and equality among their
students and faculty. The percentage of women and eth-
nic minorities among applicants and matriculants to
medical schools are duly regarded as key indicators in
academic medicine [142,143]. In the UK specifically, the
NIHR requires that universities applying for the next
round of translational research funding hold at least thesilver award of the Athena SWAN Charter for women
in science [144]. Through a competitive application pro-
cess, Athena SWAN confers bronze, silver and gold
awards, which “recognise and celebrate good practice in
recruiting, retaining and promoting women in STEMM
[Science, Technology, Engineering, Medicine and Math-
ematics] in higher education” [145]. Nevertheless, such
indicators of diversity, equality, and good practice are
not regarded as impact indicators by HEFCE and thus
were not included in the 2010 impact pilot. Tradition-
ally, inter alia, such indicators are included in the “En-
vironment” section of the RAE/REF, which will carry a
weighting of 15% in the overall outcome of the REF. In
countries with privately funded health care systems,
medical schools and academic medical centres play an
important role in improving social equity, inclusion, and
cohesion by providing uncompensated health services to
the populations most at risk of being underserved, i.e.
the uninsured and members of disadvantaged communi-
ties [146]. Measuring the extent of such health services,
both in terms of their monetary value and percentage in
the overall provision of health services, would be an im-
portant indicator of societal and economic impact. In
the UK, however, everyone has equal access to academic
medicine because the National Health Service is publicly
funded, and it is free at the point of use for everyone
who is resident in the UK. Yet, there is some variation
in the morbidity and mortality rates as well as in the
provision and quality of services across the UK, which
medical schools and university-employed clinical aca-
demics working in the NHS can address. For example,
Oxford clinical academics contributed to the design and
implementation of the National Stroke Strategy to re-
duce regional variations in the quality of stroke care and
to the establishment of a new academically-led Stroke
Unit in the Oxford John Radcliffe Hospital to improve
stroke care in Oxford and Oxfordshire. Such contribu-
tions can be captured through the measures of improved
health services and changes to public policy, as discussed
above.
Whereas health is a universal human right [147], dis-
advantaged populations in less developed countries are
trapped in the vicious circle of poverty, lack of educa-
tion, social inequalities, tropical diseases, and poor
health [148,149]. The responsibility of the international
community to uphold human dignity, equality and
equity is encompassed in the eight United Nations Mil-
lennium Development Goals (MDGs), each of which has
its own targets, with measurable indicators [150].
Through its initiative “Academic Impact”, the United
Nations seeks a commitment on the part of research-
intensive institutions of higher education to “the funda-
mental precepts driving the United Nations mandate, in
particular the realization of the universally determined
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MDGs to which medical research can contribute by fo-
cusing on the health needs of disadvantaged populations
in less developed countries:
 reduce child mortality;
 improve maternal health;
 combat HIV/AIDS, malaria, and other diseases; and
 develop a global partnership for development.
Research in tropical medicine and global health is the
major avenue for clinical scientists in Oxford to contrib-
ute to the achievement of the MDGs. The university has
tropical medicine research groups, who are permanently
based in Wellcome Trust-Oxford University centres in
Kenya, Thailand, Viet Nam, Laos, Tanzania, Indonesia
and Nepal, as well as collaborators around the world
[152]. Their activities range from basic, epidemiological
and clinical research to behavioural sciences and use of
public health evidence to monitor progress towards the
MDGs [152]. Crucially, capacity building is integral to
all tropical medicine and global health activities, and
several respondents to the impact assessment survey
emphasised that capacity building in developing coun-
tries should be included in impact indicators. As an ex-
ample of their impact in sub-Saharan Africa, several
respondents mentioned setting up clinical trials, purchas-
ing high-specification equipment, large-scale long-term
AIDS education and prevention programmes, training pro-
grammes for practitioners and researchers, and fundraising
activities. Such activities provided unique resources to the
region concerned and contributed to the development of
specialised skills, as well as having had an educational
impact on important segments of the population. It fol-
lows that in addition to the targets and measurable indi-
cators encompassed in the MDGs, impact on health
equality needs to include case studies focusing on
research-based capacity building activities, such as men-
toring the local academic and clinical workforce, develop-
ing local infrastructure, and contributing to education in
local communities.
Application of new security technologies or practices
The UK National Security Strategy recognises that in
today’s globalised world infectious diseases are among
the major security challenges, and that the highest risk is
an influenza-type pandemic [153]. It is estimated by the
government that there is a high probability of such a
pandemic occurring and that “possible impacts of a fu-
ture pandemic could be that up to one half of the UK
population becomes infected, resulting in between
50,000 and 750,000 deaths in the UK, with correspond-
ing disruption to everyday life” [153]. In view of this,
research-intensive universities and academic healthcentres have an important role in improving national
and global security by addressing the risks of infectious
diseases. In Oxford, examples of research-based activities
aimed at addressing the risk of infectious diseases in-
clude the development and patenting of new technolo-
gies that subsequently were used by pharmaceutical
companies for the preparation of H1N1 (swine flu) and
H5N1 (bird flu) vaccines. In another example, following
the declaration of a global H1N1 (swine flu) pandemic
by the World Health Organization in June 2009, clinical
scientists in Oxford, together with their colleagues in
Bristol, Exeter, London, and Southampton, conducted
the first trials of H1N1 vaccines in the UK and provided
important information to the Department of Health to
guide immunisation policy in the UK [154,155]. In order
to assess the impact of such activities, both case studies
and standardised measures of potential health outcomes
can be used.
Limitations
This article presents, to our best knowledge for the
first time, empirical data to demonstrate how impact
assessment operates and could operate in academic
clinical medicine, providing funders and the medical
research community with potential benchmarks for fu-
ture comparative studies. However, our study has sev-
eral methodological and data limitations, which entail
the possibility of bias in the results. Administrative
data for the proposed impact indicators were gathered
retrospectively. If the university and faculty members
were asked in advance to collect the types of data
required for impact assessment, the scope and granu-
larity of the data presented here are likely to have
been greater. Moreover, there are limitations on gener-
alising from a voluntary survey of a relatively small
population. Although the achieved response rate of
48.1% was relatively good, and sample proportions by
gender, career stage, and staff category were similar to
the population surveyed, there were slight discrepan-
cies between our sample and the population surveyed
(Table 1). Therefore, we cannot rule out the possibility of
self-selection bias. Finally, a compulsory census of the
entire population of clinical academics and scientists
working in the university and its partner hospitals would
have probably yielded different results. Given that univer-
sities can select which and how many faculty members to
include in their institutional submissions to the RAE/
REF [156], not all eligible faculty members are usually
submitted because universities try to maximise their
funding by selecting more accomplished faculty mem-
bers. The grounds for selection may differ between those
faculty members whose individual publications are
included in the research outputs submitted by the unit,
and those whose work is referenced in the impact part of
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pilot exercise, we surveyed only those faculty members
whose publication outputs were submitted to the 2008
RAE and thus were most likely to have their publications
submitted to the 2014 REF. As demonstrated in Table 1,
the survey population is skewed towards senior and mid-
career university scientists. If we surveyed the entire
population of clinical academics and scientists working
in the university and its partner hospitals, we would have
probably found more examples of impact, especially from
clinical practice, which would have most likely been
spread more evenly across the population.
Implications for performance-based research funding
systems
Notwithstanding methodological and data limitations,
the results of our study demonstrate the range and sig-
nificance of impacts in clinical medicine in a given uni-
versity, and enable us to critically assess the “common
menu” of impact indicators proposed by HEFCE in
2010. While the majority of the proposed indicators have
some validity, there are significant challenges in refining
the current indicators and methodologies in a number
of ways.
First, the wide range and significance of impacts cap-
tured in our study suggest that a clearer conceptualisa-
tion and standardisation of impact measures is required
in order to increase the validity and reliability of impact
assessment. The issue of validity relates to the degree of
certainty that the proposed indicators measure what they
claim to measure, i.e. research impact. For example, it is
not certain that participation on public policy commit-
tees or changes to legislation reflect one’s research activ-
ity rather than a sense of civic duty. The issue of
reliability is concerned with the consistency of measure-
ments. Without applying precise measures of impact
and criteria for the attribution of impact to specific re-
search activity across all universities, any impact assess-
ment will be inconsistent and, thus, unreliable. While
developing new standardised measures can be very
costly and challenging, this can be mitigated by concen-
trating on those indicators that are already standardised,
e.g. research income, patents, and clinical trials. The
danger of doing so, however, is that such indicators have
not been specifically designed for measuring impact and
thus can only be used as proxy indicators, and that the
probabilities of impact associated with such proxy indica-
tors are currently unknown. As discussed in the case of re-
search funding, although research funding competitively-
awarded for the purpose of improved patient care is much
more likely to lead to improved patient care in a relatively
short period of time than non-competitively-awarded
funding for basic science research, the probabilities of
achieving impact within specified time horizons and howsuch probabilities vary between different medical research
funders are currently unknown. Moreover, it should be
kept in mind that an obvious limitation of any attempt to
develop and use either direct or proxy impact indicators
for high-stakes assessments of research is that their ro-
bustness as indicators is threatened once they become tar-
gets and benchmarks for performance (Goodhart's law).
Second, the aggregation of impacts is not yet possible
because the majority of the indicators studied are not
standardised. While the data collected using the current
indicators provide evidence of the wide range and sig-
nificance of impacts and can be used for descriptive case
studies, we are not able to add the data collected from
individual researchers and teams together to create an
aggregate indicator for all faculty members in a given
university and then compare it across universities. If im-
pact assessment is to provide incentives for every faculty
member to increase the economic and social impact of
their research, then the impacts of the research of every
faculty member must be counted in. Likewise, if impact
assessment is to reward those universities that deliver
more benefits to the economy and society, then we need
to find a way to aggregate various impact indicators into
the net indicator of impact in order to compare univer-
sities. The trusty method of traditional peer review will
be stretched to the limit by the demand to weigh all the
different types of evidence for each of the indicators, as-
sess their quality, and produce consistent, meaningful
aggregate profiles for each submitting institution.
Third, there is a challenge in choosing between
quantitative and qualitative methodologies. Our study
demonstrates that some of the current indicators lend
themselves well to being quantified, but some others
can be described only qualitatively. The advantage of
using quantitative indicators is that they can be stan-
dardised and aggregated, allowing universities to use
them on a continuous basis to track their impact, com-
pare it with other universities, and recognise the contri-
bution of every faculty member, of whatever scale. At
the same time, developing valid and reliable quantita-
tive indicators and then collecting data to operational-
ise them may be costly and time intensive. The
advantage of using qualitative indicators and case stud-
ies is that there are important areas of impact that can
be captured only qualitatively, and evaluating research
impact through qualitative case studies is a relatively
quick and cost-contained alternative to quantitative
indicators. However, the emphasis on qualitative indi-
cators would stretch traditional peer review further and
concentrate on the most prominent examples of im-
pact, overlooking more modest contributions.
Fourth, our study highlights the necessity to balance
carefully incentives for basic science, translational re-
search, and clinical work across impact indicators and
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outputs because the rewards associated with impact as-
sessment and even impact indicators themselves can
modify the behaviour of individuals and universities. On
the one hand, it takes considerably more time and effort
to make basic science discoveries and design new inter-
ventions than to evaluate and bring them to market. Ex-
cessive emphasis on impact may give disproportionate
rewards to those who evaluate interventions discovered
by others and bring them to market, without giving full
recognition to basic researchers, who invent and bring
new interventions to clinical evaluation. On the other
hand, bibliometrics and other conventional indicators of
research output recognise the work of basic scientists
who publish in journals with high impact factors and are
part of large groups of authors, but may disadvantage
academic physicians who devote a significant part of
their time to clinical work and publish in specialty-
specific journals.
Fifth, there is a need for clear, collaboratively-
developed guidelines for university-based information
systems and data collection procedures. The current
university information systems and procedures were not
specifically designed to provide certain types and levels
of granularity of data required for impact assessment,
and individual researchers often do not keep a record of
events and facts that can be interpreted as impacts. As a
result, collecting impact data retrospectively puts a
strain on the scope and accuracy of impact indicators
and presents a significant burden upon universities and
their faculty. At the same time, in addition to HEFCE, a
number of publicly-funded research councils and med-
ical research charities have started asking universities
and individual grant recipients to provide evidence of
the economic and social impact of sponsored research.
For these reasons, collaboration between HEFCE and
other public funding agencies, medical research char-
ities, universities, and the wider medical research com-
munity is required in order to develop and validate a
common set of impact indicators with universal guide-
lines on data collection. This will raise the quality of im-
pact assessment, reduce the duplication of effort,
minimise the burden of collecting data for different
types of impact indicators, and allow faculty to engage
with patient populations and local communities more
effectively.
Finally, our study suggests that there is a potential for
impact indicators to be used for objectives other than
the allocation of public research funds under the REF,
i.e. medical schools can use impact indicators as part of
their social accountability strategies. Although the allo-
cation of UK government funding to universities on the
basis of impact provides universities with incentives to
increase their societal and economic impact, it isunlikely that these incentives alone can change the long-
term behaviours of universities. On the one hand, these
incentives may not be sufficiently high to change the
long-term behaviour of universities in clinical medicine,
because government funding is no longer the main
source of research funding in clinical medicine and only
a small proportion of such funding is proposed to be
allocated on the basis of impact. It is also impossible to
use legal mechanisms to enforce the accountability of
universities and individual researchers for the receipt of
research funding predicated on impact, because impact,
as it is currently defined and measured, cannot be
included in research contracts. Furthermore, universities
are highly devolved institutions, to the effect that deans
of medical schools or heads of academic departments
have no direct hierarchical powers to hold individual
researchers accountable for the actual impact of their re-
search, which, according to the current definition, is
expected to be achieved within ten years. On the other
hand, there is growing consensus among medical schools
around the world that they need to achieve and demon-
strate a greater impact on the health needs of the popu-
lations and societies they serve as part of their social
accountability project. This goal is consistent with the
goal of the government to increase the economic and so-
cial impact of publicly-funded research through the REF.
If universities, public funding agencies, medical research
charities, and the wider medical research community
collaboratively develop measurable impact indicators
and methodologies that enable universities to claim,
track and compare the impacts of their research in a
transparent and rigorous manner on a continuous basis,
universities can use impact assessment as part of their
social accountability strategies. This way, the medical re-
search community can adjust their long-term behaviour
in line with the requirements of social accountability
and, in doing so, once again prove to the public and tax-
payers its right to professional autonomy and self-
regulation.
Conclusion
Overall, the evidence from our study supports the claim
that assessing impact is feasible, but that current meth-
odologies will need to be significantly improved before
using measurable impact indicators as a basis on which
to change the long-term behaviour of universities. The
impact indicators and methods discussed in this paper
can be used successfully to identify the many areas
where impacts (in the REF sense) occur and the wide
range of forms that they take, in order to build an evi-
dence base for descriptive case studies of impact and im-
pact statements as part of the REF peer review in 2014.
However, a quinquennial peer review of descriptive case
studies and statements, and the funding incentives
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change in the long-term behaviour of universities in the
field of clinical medicine. To do so, universities would
need to be able to claim, track and compare the impacts
of their research in a transparent and rigorous manner
on a continuous basis as part of their social accountabil-
ity strategies. This is a different task, which would re-
quire further debate about impact assessment to move
away from a quinquennial peer review of descriptive
evidence to a continuous monitoring and analysis of
measurable impact indicators. The latter would entail
developing a set of valid and reliable indicators; robust
methodologies for attributing and aggregating impact;
carefully balanced incentives for basic science, transla-
tional research, and clinical work; and clear guidelines
for universities. Given the scope and complexity of
these tasks, universities and the wider medical research
and academic community have an important role to play
in shaping public understandings of research impacts, of
the nature of evidence required to claim and assess
impacts, and of the robustness of methodologies and
indicators for impact assessment in the REF 2014 and
beyond.
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